Preferred Label : Mcleod syndrome;
Symbol : MCLDS;
CISMeF acronym : MCLDS;
Type : Phenotype, molecular basis known;
Alternative titles and symbols : Mcleod phenotype; Neuroacanthocytosis, mcleod type;
Description : Hematologically, McLeod syndrome is characterized by the absence of red blood cell
Kx antigen, weak expression of Kell red blood cell antigens, acanthocytosis, and compensated
hemolysis. Most carriers of this McLeod blood group phenotype have acanthocytosis
and elevated serum creatine kinase levels and are prone to develop a severe neurologic
disorder resembling Huntington disease (143100). Onset of neurologic symptoms ranges
between 25 and 60 years (mean onset 30-40 years), and penetrance appears to be high.
Additional symptoms include generalized seizures, neuromuscular symptoms leading to
weakness and atrophy, and cardiomyopathy mainly manifesting with atrial fibrillation,
malignant arrhythmias, and dilated cardiomyopathy (summary by Jung et al., 2007).
The cooccurrence of McLeod syndrome and chronic granulomatous disease (CGD; 306400)
results from a contiguous gene deletion (Francke et al., 1985).;
Inheritance : X-linked;
Molecular basis : Caused by mutation in the Kell blood group protein gene (XK, 314850.0001);
Laboratory abnormalities : Elevated serum creatine levels;
Prefixed ID : #300842;
Origin ID : 300842;
UMLS CUI : C0398568;
Automatic exact mappings (from CISMeF team)
Currated CISMeF NLP mapping
Genes related to phenotype
HPO term(s)
ORDO concept(s)
Semantic type(s)
UMLS correspondences (same concept)